Quoin Pharma Executives Lead Insider Buys; Caterpillar, Airbnb Insiders Sell Stock

Executives at specialty pharmaceutical company Quoin Pharmaceuticals led a series of notable insider purchases, while insiders at major firms including Caterpillar and Airbnb sold significant blocks of stock, according to regulatory filings disclosed Tuesday.

Notable Insider Purchases

Top executives at Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) showed confidence in the company through coordinated purchases on August 31, 2026. CEO Michael Myers and COO Denise P. Carter each acquired 20,490 American Depositary Shares (ADSs) in a private placement.

• Each executive's transaction was valued at $99,991, with a purchase price of $4.88 per ADS.
• Following the purchase, Myers directly holds 37,713 ADSs.
• The source noted the stock has since gained over 33% from the executives' purchase price.

Other significant insider buying activity included:

• FTC Solar, Inc. (NASDAQ:FTCI): Director Shaker Sadasivam purchased 101,083 shares for approximately $271,913 on August 28.
• Aura Minerals Inc. (NASDAQ:AUGO): An entity associated with director Bruno Sousa Mauad reported net buying activity, acquiring shares worth roughly $21.79 million while selling shares valued at $13.66 million.
• CuriosityStream Inc. (NASDAQ:CURI): CEO Clinton Larry Stinchcomb bought 20,000 shares for $52,060 as the stock traded near its 52-week low.

Significant Insider Sales

On the sell side, Caterpillar Inc. (NYSE:CAT) CEO Joseph E. Creed sold 32,901 shares of common stock for a total of approximately $26.2 million. The sales, executed on August 28, followed his exercise of 44,403 employee stock options at a much lower price.

Ad

At Airbnb, Inc. (NASDAQ:ABNB), Chief Strategy Officer Nathan Blecharczyk sold shares totaling approximately $13.45 million in late August. The transactions occurred as Airbnb's stock was trading near its 52-week high.

Other large sales were reported at:

• ORTHOPEDIATRICS CORP (NASDAQ:KIDS): Major shareholder Squadron Capital LLC sold 336,831 shares for a total of $7.76 million.
• Oruka Therapeutics, Inc. (NASDAQ:ORKA): CEO Lawrence Otto Klein sold 75,000 shares for approximately $6.89 million. The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan established in May 2026.

Context for Investors

Insider transactions are closely watched by investors for potential signals about a company's future performance. Substantial purchases by top executives can indicate strong confidence in the firm's prospects.

Conversely, insider sales are not always a negative indicator. Executives may sell shares for a variety of personal financial reasons, including portfolio diversification, tax planning, or funding large purchases. Therefore, investors typically view patterns of buying as a more direct signal than isolated sales. The data should be considered as one component of a broader investment analysis.